Purification and functional assay of pluripotent hematopoietic stem cells.

C. Peschle, R. Botta, R. Müller, M. Valtieri, B. Ziegler
{"title":"Purification and functional assay of pluripotent hematopoietic stem cells.","authors":"C. Peschle, R. Botta, R. Müller, M. Valtieri, B. Ziegler","doi":"10.1046/J.1468-0734.2001.00029.X","DOIUrl":null,"url":null,"abstract":"Hematolymphopoietic stem cells (HSC) have the capacity for extensive self-renewal and pluripotent myelolymphoid differentiation. Recent studies have emphasized the heterogeneity of human HSC subsets in terms of proliferative and self-renewal capacity. In the NOD-SCID (nonobese diabetic-severe combined immunodeficient) mouse xenograft assay, most CD34+38- stem cell clones proliferate at early times, but then disappear, whereas only few clones persist: possibly, the latter ones consist of long-term engrafting CD34+38- HSC expressing the KDR receptor (i.e. the vascular endothelial growth factor receptor II). In this regard, isolation of the small KDR+ subset from the CD34+ hematopoietic progenitors (and possibly from the CD34-lin- population) may provide a novel and effective approach for the purification of long-term proliferating HSC. More importantly, KDR+ HSC isolation will pave the way to cellular/molecular characterization and improved functional manipulation of HSC/HSC subsets, as well as to innovative approaches for HSC clinical utilization, specifically transplantation, transfusion medicine and gene therapy.","PeriodicalId":82483,"journal":{"name":"Reviews in clinical and experimental hematology","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2001-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1046/J.1468-0734.2001.00029.X","citationCount":"17","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in clinical and experimental hematology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1046/J.1468-0734.2001.00029.X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 17

Abstract

Hematolymphopoietic stem cells (HSC) have the capacity for extensive self-renewal and pluripotent myelolymphoid differentiation. Recent studies have emphasized the heterogeneity of human HSC subsets in terms of proliferative and self-renewal capacity. In the NOD-SCID (nonobese diabetic-severe combined immunodeficient) mouse xenograft assay, most CD34+38- stem cell clones proliferate at early times, but then disappear, whereas only few clones persist: possibly, the latter ones consist of long-term engrafting CD34+38- HSC expressing the KDR receptor (i.e. the vascular endothelial growth factor receptor II). In this regard, isolation of the small KDR+ subset from the CD34+ hematopoietic progenitors (and possibly from the CD34-lin- population) may provide a novel and effective approach for the purification of long-term proliferating HSC. More importantly, KDR+ HSC isolation will pave the way to cellular/molecular characterization and improved functional manipulation of HSC/HSC subsets, as well as to innovative approaches for HSC clinical utilization, specifically transplantation, transfusion medicine and gene therapy.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
多能造血干细胞的纯化及功能分析。
造血干细胞(HSC)具有广泛的自我更新和多能髓淋巴细胞分化的能力。最近的研究强调了人类HSC亚群在增殖和自我更新能力方面的异质性。在NOD-SCID(非肥胖糖尿病-严重联合免疫缺陷)小鼠异种移植试验中,大多数CD34+38-干细胞克隆在早期增殖,但随后消失,而只有少数克隆持续存在:可能,后者包括长期移植表达KDR受体(即血管内皮生长因子受体II)的CD34+38- HSC。在这方面,从CD34+造血祖细胞(也可能来自CD34-lin-群体)中分离KDR+小亚群可能为纯化长期增殖的HSC提供一种新的有效方法。更重要的是,KDR+ HSC的分离将为细胞/分子表征和改进HSC/HSC亚群的功能操作铺平道路,并为HSC的临床应用,特别是移植、输血医学和基因治疗提供创新方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Recent developments in new and old viral infections. Prophylaxis and treatment of bacterial infections: do we need new strategies? New therapies in onco-hematology and new infectious risk factors. Microbiologic consequences of new approaches to managing hematologic malignancies. Infections in hematologic patients: the future.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1